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Abstract
Background and aims: Bariatric surgery remains a main-
stay for treatment of morbid obesity. However, long-term 
adverse outcomes include chronic abdominal pain and 
persistent opioid use. The aim of this review was to 
assess the existing data on prevalence, possible mech-
anisms, risk factors, and outcomes regarding chronic 
abdominal pain and persistent opioid use after bariatric 
surgery.
Methods: PubMed was screened for relevant literature 
focusing on chronic abdominal pain, persistent opioid 
use and pharmacokinetic alterations of opioids after bari-
atric surgery. Relevant papers were cross-referenced to 
identify publications possibly not located during the ordi-
nary screening.
Results: Evidence regarding general chronic pain status 
after bariatric surgery is sparse. However, our litera-
ture review revealed that abdominal pain was the most 
prevalent complication to bariatric surgery, presented 
in 3–61% of subjects with health care contacts or read-
missions 1–5 years after surgery. This could be explained 
by behavioral, anatomical, and/or functional disorders. 
Persistent opioid use and doses increased after bariat-
ric surgery, and 4–14% initiated a persistent opioid use 
1–7  years after the surgery. Persistent opioid use was 
associated with severe pain symptoms and was most 
prevalent among subjects with a lower socioeconomic 
status. Alteration of absorption and distribution after 
bariatric surgery may impact opioid effects and increase 
the risk of adverse events and development of addiction. 
Changes in absorption have been briefly investigated, 
but the identified alterations could not be separated 
from alterations caused solely by excessive weight loss, 
and medication formulation could influence the find-
ings. Subjects with persistent opioid use after bariatric 
surgery achieved lower weight loss and less metabolic 
benefits from the surgery. Thus, remission from comor-
bidities and cost effectiveness following bariatric surgery 
may be limited in these subjects.
Conclusions: Pain, especially chronic abdominal, and 
persistent opioid use were found to be prevalent after 
bariatric surgery. Physiological, anatomical, and pharma-
cokinetic changes are likely to play a role. However, the 
risk factors for occurrence of chronic abdominal pain and 
persistent opioid use have only been scarcely examined as 
have the possible impact of pain and persistent opioid use 
on clinical outcomes, and health-care costs. This makes 
it difficult to design targeted preventive interventions, 
which can identify subjects at risk and prevent persistent 
opioid use after bariatric surgery. Future studies could 
imply pharmacokinetic-, pharmacodynamics-, and phys-
iological-based modelling of pain treatment. More atten-
tion to social, physiologic, and psychological factors may 
be warranted in order to identify specific risk profiles of 
subjects considered for bariatric surgery in order to tailor 
and optimize current treatment recommendations for this 
population.
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1   Introduction
The World Health Organization has officially declared 
obesity as a global epidemic. Currently, more than 
650 million (13%) adults suffer from obesity, defined as a 
body mass index (BMI) ≥30, and numbers are increasing 
rapidly with more subjects falling within both the severe 
obesity category, defined as BMI ≥35, and the morbidly 
obesity category, defined as a BMI ≥40 [1–4]. Comorbidi-
ties, such as cardiovascular diseases, diabetes mellitus, 
and musculoskeletal disorders are common amongst 
subjects with morbid obesity [2, 5]. Additionally, chronic 
visceral pain is highly represented and a clear association 
between increasing BMI and chronic pain has been dem-
onstrated possibly caused by a combination of lifestyle 
and mechanical, chemical, and psychological media-
tors [6, 7]. Preventive programs for subjects with morbid 
obesity have been executed, to reduce excessive weight 
and limit subsequent morbidity. However, even compre-
hensive lifestyle changes were only associated with inter-
mediate weight loss in most subjects, and many regained 
weight [7, 8].
Bariatric surgery offers the possibility to retain a 
large long-term weight loss and minimize associated 
comorbidities compared to non-surgical options. There-
fore, it has been a mainstay of treatment for morbid 
obesity and severe obesity with coexisting comorbidity 
for decades [4, 9–11].
2   Bariatric surgery
The three most well-known and commonly performed 
bariatric surgeries are Roux-En-Y gastric bypass (RYGB), 
laparoscopic sleeve gastrectomy (LSG) and laparoscopic 
adjustable gastric band (LAGD) (Fig. 1). Each procedure 
has its own advantages and disadvantages, which should 
be taken into account to ensure the optimal selection of 
surgery for the individual subjects [12, 13].
2.1   Roux-En-Y gastric bypass
A RYGB creates a small pouch (approx. 30 mL in volume), 
from the upper region of the stomach, which is connected 
to the jejunum. The remaining stomach with the adjacent 
duodenum is connected further down the small intestine, 
hereby generating a Y-configuration and bypassing orally 
ingested substances (Fig. 1A). The altered anatomy limits 
ingestion of large food quantities. Moreover, secretion 
of gut hormones is minimized, stimulating satiety and 
suppressing hunger. This imply the main mechanisms 
explaining the large weight loss after the surgery. Diges-
tion and absorption of calories from fat, carbohydrates 
and proteins are not significantly affected. However, the 
hormonal and neural changes have abrupt effects on type 
2 diabetes [8, 11, 14].
The RYGB results in the largest long-term weight loss 
compared to other surgeries [15]; however, vitamin- and 
mineral deficiency is a common challenge, resulting in 
severe consequences such as anemia, osteoporosis and 
neurological disorders [16]. Lifelong supplement con-
sumption and dietary regulations are therefore essential. 
The RYGB is also a more complex and invasive operation 
compared to LSG and LAGB, resulting in longer hospitali-
zation and higher complication rates [17]. Nevertheless, 
it was the most frequently performed bariatric surgery 
worldwide until 2014, wherefrom it was surpassed by LSG 
[12, 13, 18].
A B C
Fig. 1: Illustrations of a normal stomach and the three most common bariatric surgeries. The anatomy of a normal stomach, and the 
anatomical changes, after; (A) Roux-EN-Y Gastric bypass (RYGB), (B) Laparoscopic Sleeve Gastrectomy (LSG) and (C) Laparoscopic Adjustable 
Gastric Banding (LAGB).
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2.2   Laparoscopic sleeve gastrectomy
During a LSG approximately 80% of the stomach is 
 permanently removed, by creating a tubular pouch 
(Fig. 1B). Thus, the procedure includes no foreign devices 
or bypassing of orally ingested substances. Weight loss 
is achieved due to the reduced gut volume, less produc-
tion of gastric acids and digestive enzymes, which affects 
digestion, absorption and the gut hormones with similar 
outcomes as mentioned for RYGB [17, 19].
2.3   Laparoscopic adjustable gastric band
The LAGB divides the stomach into a smaller upper 
stomach and a larger lower stomach (Fig. 1C). This pro-
cedure is reversible and the band can be adjusted to 
prompt weight loss or minimize unpleasant side-effects 
(e.g. nausea). Furthermore, no cutting or resection is 
performed. Thus, early postoperative complications, 
malabsorption, and dumping symptoms are rare. On the 
downside, LAGB is the least effective procedure in obtain-
ing large, long-term weight loss and has the highest rate 
of re-operation, primarily due to complications caused 
by the device. Hence, the number of subjects undergoing 
LAGB is declining and many surgeons abandon this pro-
cedure [13, 17].
3   Aim
The aim of this review was to assess the existing data on 
prevalence, possible mechanisms, risk factors, and out-
comes regarding occurrence of chronic abdominal pain 
and persistent opioid use after bariatric surgery.
4   Methods
The present study is based on three different PubMed 
searches (http://www.ncbi.nlm.nih.gov/pubmed) from 
February to May 2019, on the subject “chronic abdominal 
pain and persistent opioid use after bariatric surgery.” 
The searches included multiple medical subject headings 
(MeSH) on bariatric surgery, weight loss, chronic abdominal 
pain, gastrointestinal symptoms, opioids, pharmacokinetic 
alterations and bioavailability. Additionally, PubMed was 
searched using similar free-text word terms on the same 
topics. Only relevant original articles and reviews pub-
lished in English were included. Case reports, editorial 
letters, and reports on symptoms and medication in the 
early postoperative phase (≤30 days) and articles, which 
in different manners did not relate to the scope, were 
excluded. Bibliographies of relevant articles were cross-
referenced to identify more articles of interest. There were 
no restraints for the year of publication.
5   Abdominal pain after bariatric 
surgery
5.1   Prevalence
Insufficient data exist regarding the development of 
chronic pain following bariatric surgery, and the actual 
pain intensity [20]. Excessive weight loss may intensely 
improve e.g. musculoskeletal pain conditions after bari-
atric surgery [21]. Results from a survey-based study from 
Norway indicate that subjects suffering from joint pain 
decreased from 71% before surgery to 57% 5  years after 
bariatric surgery [22]. However, subjects may become more 
vulnerable to chronic pain conditions, due to increased 
pain sensitivity, decreased pain detection thresholds, and 
altered pain processing after bariatric surgery [21].
The results from a survey-based study by Grib-
sholt et  al. (2016) demonstrated that the most common 
symptom, resulting in 34.2% of the health care contacts 
after RYGB was abdominal pain. The risk was higher 
among women, young subjects, smokers, unemployed 
subjects, and subjects with symptoms from previous sur-
geries [23]. In several studies abdominal pain has been 
identified as the most common symptom, causing addi-
tional health care contacts and hospital readmissions 
with a prevalence up to 61.4% (Table 1) [8, 22–31]. Chronic 
abdominal pain was found to be associated with reduced 
health related quality of life [22]. Even though bariatric 
surgery is effective for obtaining weight loss and reduc-
ing obesity related comorbidity, the number of symptoms, 
medication use, and health care contacts after surgery 
continued to be high and represents a significant burden 
on the subjects as well as upon the society, indicating, 
that general health conditions are not normalized in these 
subjects [23, 24, 32]. In general, studies focusing on longi-
tudinal evaluations from before and after bariatric surgery 
to evaluate the potential casual relationships between 
bariatric surgery and chronic abdominal pain are lacking. 
Additionally, evidence is primarily restricted to studies on 
RYGB surgery, e.g. only one study investigating abdominal 
pain separate after LSG have been identified in the present 
review [8, 22–26, 28–30].
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Table 1: Prevalence of abdominal pain after bariatric surgery.
Study Design Results
Cho et al. [24] Retrospective study on medical records of subjects 
undergoing LRYGB surgery at a single hospital admitted to 
emergency care. n = 733
The most frequent complaint in the 
emergency room was abdominal pain, which 
were presented in 61.4% of the subjects
Saunders et al. [25] Hospital records for 1-year readmission of subjects 
undergoing bariatric surgery in a single US hospital 
setting, for 31 months. n = 1,939
Overall 1-year readmission rate was 18.8%. 
LAGB had the lowest (12.7%) and RYGB the 
highest rate (24.2%). Abdominal pain was 
leading cause of readmission (11.8%)
Gribsholt et al. [23] Survey on self-reported outcomes (2014) in subjects 
undergoing RYGB surgery in the Central Region of 
Denmark 2006–2011. Median follow-up 4.7 years. 
n = 2,238 undergoing RYGB, n = 89 controls
63.7% responded the survey. 88.6% reported 
≥1 symptoms. 67.6% of subjects were in 
contact with the healthcare within follow-up, 
compared to 34.8% controls from the general 
population. 34.2% of healthcare contacts 
were caused by abdominal pain
Pernar et al. [26] Study of subjects who underwent RYGB surgery and were 
admitted to emergency department (2005–2015). To 
examine association between clinical parameters and 
abdominal CT scans. n = 1,643 undergoing RYGB surgery
676 subject visited the emergency 
department. Abdominal pain was presented 
in 624 (92%) visitors. No clinical or laboratory 
parameter were associated with the imaging 
results
Hogestol et al. [22] Prospective Norwegian survey on 5-year follow-up of 
subjects undergoing RYGB surgery. n = 165
33.8% reported chronic abdominal pain. 
Among these subjects 48.8% reported 
indigestion and 29.1%, reported IBS. 18.5% 
had abdominal pain prior to RYGB
Pierik et al. [27] Database study in Amsterdam from November 2007 
to April 2015 on prevalence and predictive factors of 
unexplained abdominal pain after bariatric surgery. 
n = 1,788 subjects underwent LRYGB (1,361) or LSG (118)
Average follow-up was 33.5 months. 21.6% 
subjects had abdominal pain and 7.4% 
experienced unexplained abdominal pain 
after bariatric surgery
Altieri et al. [28] SPARCS database study on all SG surgeries 2011–2013, 
including at least 1-year follow-up, for incidence of 
emergency department visits and hospital readmissions. 
n = 14,080 subjects who underwent SG surgery
33.9% visited emergency department in 
follow-up. 53.9% unrelated to surgery. 
11.1%, presented with abdominal pain. 
One-year readmission rate was 12.5%. 
Readmission causes were 41.7% unrelated 
to surgery, 8% related, and 3.0% abdominal 
pain
Blom-Hogestol et al. [29] Prospective Norwegian survey on random selected 
subjects undergoing RYGB surgery in a single hospital 
setting, with 5-year follow-up. n = 234
71% were readmitted in follow-up, and 
97% responded to the survey. Thirty-four 
percent reported chronic abdominal pain, 
caused by internal herniation, dumping, 
food intolerance, gallstones, or IBS. (Same 
population as Hogestol et al. [22])
Gribsholt et al. [30] Cohort study on all subjects undergoing RYGB surgery in 
Denmark 2006–2010, and matched general population 
controls. Follow-up for median 4.2 years. n = 9,985 
undergoing RYGB, n = 247,375 controls
Readmissions in 3.3% subjects undergoing 
RYGB surgery within 30 days and 23.9% 
in follow-up. Fifteen percent admitted with 
abdominal pain. Admission rates before RYGB 
were 11.5 vs. 5.9 in controls per 100 person-
years, increasing to 24.9 vs. 7.1 after surgery
Jakobsen et al. [8] Cohort in Norwegian outpatient center 2005–2010 
and follow-up from 2006 to 2015 Bariatric surgery or 
specialized medical obesity treatment. n = 932 surgical 
(855 RYGB, 69 SG and 8 other), n = 956 medical treatment
The rate of abdominal pain in subjects 
undergoing bariatric surgery (26.1%) 
was higher than in subjects with medical 
treatment (RR: 1.9, ARD: 12.6% points)
Mala et al. [31] Review of prevalence, evaluations, etiology, and 
treatment of abdominal pain specific to RYGB surgery 
from PubMed searches and clinical experience
Limited evidence suggest about 30% subjects 
may experience chronic abdominal pain after 
RYGB, with diverse etiology and undefined 
cause of pain for a subset of subjects
ARD = absolute risk difference; GI = gastrointestinal; IBS = irritable bowel syndrome; LAGB = laparoscopic adjustable gastric band; 
LRYGB = laparoscopic Roux-En-Y gastric bypass; LSG = laparoscopic sleeve gastrectomy; n = number of subjects; RYGB = Roux-En-Y gastric 
bypass; SG = sleeve gastrectomy; US = United States.
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5.2   Abdominal pain pathogenesis
The etiologies of abdominal pain after bariatric surgery 
are diverse, and several causes have been suggested, 
including; (1) behavioral, dietary disorders such as over- 
and rapid eating resulting in mechanical distension of the 
pouch or reduced stomach; (2) functional disorders such 
as constipation, diarrhea, irritable bowel syndrome and 
dumping syndrome; (3) biliary disorders such as chole-
lithiasis, choledocholithiasis or sphincter of oddi dysfunc-
tion; (4) pouch or remaining stomach disorders such as 
peptic ulcer disease, gastro-gastric fistula, gastroesopha-
geal reflux disease and hiatus hernia; (5) small intestine 
disorders such as abdominal wall and internal hernias 
[30, 33–35]. However, unfortunately the pain etiology 
remains undefined in 23–43% of subjects with abdominal 
pain after RYGB, and the associations after other forms of 
bariatric surgery are even less evident [28, 30, 34]. Thus, 
a thorough understanding of the pathogenesis will natu-
rally improve clinical outcomes as mechanism based 
management can be initiated to prevent chronic abdomi-
nal pain after bariatric surgery [28, 33].
5.3   Pharmacological treatment
Symptom improvement on chronic abdominal pain could 
be obtained from dietary guidance, e.g. if the cause is 
a behavioral, dietary disorder, whereas in other cases 
surgery or specific medical treatment is used, e.g. in peptic 
ulcer. However, in some cases pharmacological pain treat-
ment is needed [26, 28]. The World Health Organizations 
analgesic ladder was developed for the treatment of cancer 
pain, but is also used in the treatment of chronic abdomi-
nal/visceral pain as there are no treatment guidelines 
specifically for chronic abdominal pain. Orally adminis-
tered analgesics are suggested in the following order: non-
opioids [non-steroidal anti-inflammatory drugs (NSAIDs) 
and acetaminophen]; then weak opioids (e.g. tramadol), 
on demand; then strong opioids (e.g. morphine), until 
sufficient pain relief is achieved. Adjuvant analgesics e.g. 
antidepressants or anticonvulsants, might also provide 
analgesic effects and could additionally be used to calm 
fears and anxiety [26, 36].
Acetaminophen is a widely used non-opioid with 
analgesic and antipyretic effects through central and 
peripheral non-opioid mechanisms [37]. In contrast to 
NSAIDs, acetaminophen possesses no clinically relevant 
anti-inflammatory characteristics. However, it is preferred 
over NSAIDs, due to its limited gastrointestinal side-effect 
profile. Acetaminophen treatment is often continued 
when additional stronger analgesics are needed. Non-
opioids are often insufficient for a satisfactory abdomi-
nal/visceral pain relief. Thus, opioids are widely used in 
the management of subjects experiencing severe visceral 
pain [38]. Opioids produce significant pain relief through 
direct effects on the visceral pain pathways. However, due 
to side-effects in the gastrointestinal and central nervous 
system, it is essential to monitor the subjects closely and 
manage individual risk-benefit profiles and to prevent 
development of constipation and addiction. Adjuvant 
analgesics may be relevant as supplement and have a spe-
cific role in the presence of central sensitization or major 
psychological components [36].
6   Opioid use after bariatric surgery
For decades, efforts to improve general patient-care in the 
management of chronic pain have triggered an undesir-
able increase in the number of opioid prescriptions and 
persistent users [39]. The increased incidence of opioid 
overprescribing, abuse, misuse, addiction, and over-
dosing has been an unexpected consequence [7, 39–41]. 
Sufficient acute multimodal pain management, includ-
ing opioid treatment, has been found to be an important 
instrument after any surgery, including bariatric surgery, 
since this reduces the risk of postoperative chronic pain 
[42, 43]. However, the efficacy and safety of persistent 
opioid treatment is controversial [32, 40]. Bariatric surgery 
is associated with short-term complications, but there are 
only few studies on long-term outcomes, including long-
term opioid use [8, 41].
6.1   Prevalence
Most studies on opioid use after bariatric surgery are based 
on US insurance-databases or surveys, but European 
studies have also been published. In general, the results 
showed that opioid use was common in the subject before 
bariatric surgery, but increased afterwards (Table 2) [8, 44, 
46–49]. In a survey-based study from Michigan it was iden-
tified that 21.5% of subjects undergoing bariatric surgery 
reported to have used opioids the year before surgery 
and in another US study it was identified that 35.9% used 
opioids on demand, and 8.0% used opioids persistently, 
before surgery. Among the persistent users before bariat-
ric surgery, 77.5% continued a persistent use, 19.5% used 
opioids on demand, whereas only 3.0% reported no opioid 
use the following year [40, 47]. Contrary, results from 
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another study showed a prevalence of 14.7% self-reported 
opioid users before surgery, which decreased to 12.9% at 
6 months after surgery. However, the prevalence of opioid 
users increased to 20.3% after 7  years [7].  Moreover, the 
ingested opioid doses was found to increase following 
bariatric surgery [40, 44, 46]. In a Swedish study it was 
Table 2: Prevalence of persistent opioid use after bariatric surgery.
Study Design Results
Raebel et al. [40] Retrospective US cohort on opioid use 1-year before/after 
bariatric surgery 2005–2009. Chronic use, defined as ≥10 
opioid dispensing over ≥90 days, or dispensing 120-day supply. 
n = 11,719
Before surgery, 56% used no opioids, 35.9% 
used opioids on demand, and 8.0% used 
opioids persistently. Among persistent users, 
77.5% continued persistent use, 19.5% used 
opioids on demand, and 3.0% discontinued 
opioids 1-year after surgery
Raebel et al. [44] Retrospective US cohort on opioid use in subjects undergoing 
bariatric surgery who were non-persistent opioid users 1-year 
before surgery 2005–2009. Chronic use, defined as ≥10 opioid 
dispensing over ≥90 days, or dispensing 120-day supply. 
n = 10,643
4.0% became persistent opioid users 1-year 
after surgery. Risk factors were pre-surgery 
analgesics, antianxiety agents, tobacco, and 
non-laparoscopic band procedures
Tabibian et al. [20] Retrospective case-control study on opioid records in a pain 
rehabilitation center 2008–2012. Compare pain treatment 
outcomes for subjects undergoing bariatric surgery to non-
bariatric controls matched on age, gender, and smoking. n = 106 
cases, n = 106 controls
Subjects undergoing bariatric surgery used 
more OME at discharge, than matched 
non-bariatric subjects with pain. Subjects 
undergoing bariatric surgery had higher rates 
of benzodiazepine at discharge (33 vs. 19%) 
and were less likely to complete treatment 
(87 vs. 97%). At admission, mean OME was 
127.3 mg in cases and 88.3 mg in controls
Brummet et al. [45] Retrospective US cohort on insurance claims in opioid-naïve 
subjects undergoing minor and major surgery e.g. bariatric 
surgery 2013–2014
n = 36,177 subjects undergoing general surgery
Rates of new persistent opioid use were 
similar in the minor and major surgery groups 
5.9–6.5%. >7% subjects were new persistent 
users after bariatric surgery
King et al. [7] Survey on longitudinal assessment of opioid use as  
self-reported daily, weekly, or on demand after Bariatric  
Surgery in US. n = 2,258
Before surgery, 14.7% used opioids. This 
decreased to 12.9% after 6 month, but 
increased to 20.3% after 7 years. 5.8% were 
new persistent users at 6 month and 14.2% 
at 7 years. New persistent use was associated 
with; health insurance, pre-surgery pain, 
subsequent surgeries, and other analgesic use
Wallén et al. [46] Retrospective Swedish cohort of the opioid pattern following 
RYGB in subjects with a high and low opioid consumption pre-
surgery. n = 35,612
2.2% of subjects who used <10 mg OME daily 
before surgery used >10 mg OME daily 2 years 
after RYGB
Jakobsen et al. [8] Cohort Norway outpatient center 2005–2010 and follow-up from 
2006 to 2015 Bariatric surgery or specialized medical obesity 
treatment n = 932 surgical (855 RYGB, 69 SG and 8 other), 
n = 956 medical treatment
New onset of opioid use in subjects 
undergoing bariatric surgery (19.4%) was 
higher than after medical treatment (RR: 1.3, 
ARD: 3.6% points)
Smith et al. [47] Cohort on new persistent opioid use in subjects undergoing 
bariatric surgery in Michigan, 2006–2016. Patient-reported 
survey on opioid use before and at 1 year after surgery. 
n = 27,799
21.5% used opioids before surgery. 6.3% were 
new persistent opioid users at 1-year post-
surgery. New persistent opioid users lost less 
weight, had worse psychological wellbeing, 
body image, and depression, reported less 
satisfaction by the surgery
Heinberg et al. [21] Non-systematic review of opioid use after bariatric surgery Identified four large prospective studies, 
examining the prevalence of continuing/
initiating opioids after bariatric surgery 
(Raebel et al. [40, 44], Wallén et al. [46], King 
et al. [7]). The studies indicate that bariatric 
surgery does not reduce opioid use
ARD = absolute risk difference; n = number of subjects; OME = oral morphine equivalent doses; RR = relative risk; RYGB = Roux-En-Y gastric 
bypass; SG = sleeve gastrectomy; US = United States.
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found, that 2.2% of subjects who used <10 mg oral mor-
phine equivalent daily before surgery used >10  mg oral 
morphine equivalent daily 2 years after RYGB-surgery [46]. 
Unfortunately, all the studies lack information on clinical 
indications for the opioid use [44].
Many subjects initiated a persistent opioid use after 
bariatric surgery. Raebel et al. (2014) found that 4.0% of 
non-persistent users before surgery initiated persistent 
opioid use the year after surgery [44]. In other studies it was 
identified that >6.3% of subjects, without previous opioid 
use, initiated persistent opioid use the year after bariatric 
surgery [45, 47]. Additionally, a study found that 5.8% of 
subjects without opioid use before bariatric surgery used 
opioid 6 month after and 14.2% used opioids after 7 years 
[7]. Studies on opioid use after bariatric surgery, has pre-
viously been reviewed, but studies comparing opioid ini-
tiation in medical treated controls with morbid obesity 
were not considered [21]. A cohort-study from Norway 
compared comorbidity- and medication-changes among 
subjects with morbid obesity undergoing bariatric surgery 
or medical treatment. They found, that the absolute risk 
of initiating persistent opioid use after surgical treatment 
(19.4%) was higher than after medical treatment (relative 
risk: 1.3, absolute risk difference: 3.6) [8]. Additionally, 
subjects suffering from chronic pain after bariatric surgery 
were less likely to complete a pain rehabilitation program, 
and used higher opioid dose at discharge, than matched 
non-bariatric subjects with chronic pain at the same pain 
rehabilitation center [50]. Many of the subjects with per-
sistent opioid use after bariatric surgery, used opioids at 
least occasionally before surgery [40, 44].
In summary, it is concerning that the prevalence of 
subjects using opioids increases after bariatric surgery, 
and that opioid doses seems to increase. This emphasizes 
the importance of identifying risk of initiating persistent 
opioid use and of improving specific management of pos-
sible chronic pain in subjects undergoing bariatric surgery 
[32, 44]. Future strategies, for better follow up of subjects 
after surgery to prevent long-term opioid use, are needed.
6.2   Altered drug pharmacokinetics after 
bariatric surgery
The anatomical and physiological changes following espe-
cially RYGB and LSG impact the pharmacokinetics of some 
drug classes, potentially leading to therapeutic failure or 
increased occurrence of side-effects [18, 51, 52]. Especially, 
the major reduction in gastric volume can affect the rate 
and extent of absorption after oral administration due 
to reduced mucosal surface area, altered pH and gastric 
transit times, which influences disintegration of tablets 
with pH-sensitive coatings and/or the dissolution of the 
drug substance [53]. In theory, all four parameters of drug 
disposition; “absorption, distribution, metabolism and 
excretion” (ADME), might be affected by the altered gas-
trointestinal physiology (Fig. 2). However, the effect of 
the bariatric procedure is difficult to disentangle from the 
effect of the weight loss [54–56].
In subjects undergoing RYGB, gastrointestinal 
first-pass metabolism and efflux could be reduced, 
as cytochrome P450 enzymes and drug transporters 
expressed in duodenum are bypassed. Additionally, 
surgery results in shorter intestinal transit times, which 
limits drug absorption [57–59]. The impact on bile salt sol-
ubilisation and lipid degradation of tablets based on lipo-
philic constituents may be altered in subjects undergoing 
RYGB. However, results from different studies have shown 
deviating results with regards to the production and deliv-
ery of pancreatic juices containing bile salts and lipases 
in subjects undergoing bariatric surgery. Furthermore, 
enterohepatic circulation could potentially be disrupted, 
affecting absorption of some drug substances [60, 61].
Fig. 2: Factors affecting the pharmacokinetic profile. Different 
factors could affect the absorption, distribution, metabolism and 
excretion (ADME) of a given drug. Factors shown in pale blue circles 
are factors related to the weight loss, and factors shown in dark blue 
circles are factors related to the altered gastrointestinal physiology 
induced by the operation. Although the effect of the weight loss 
may be hard to distinguish from the effect of the surgery, the figure 
illustrates, many more possible factors to consider than only weight, 
when a dosing regime is set in a subject who underwent bariatric 
surgery.
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Altered pharmacokinetics is less evident in subjects 
undergoing LAGB, since the gastrointestinal tract is pre-
served. However, a large weight loss affects drug dis-
tribution, due to decreased lean body mass, and drug 
metabolism, as steatohepatitis gradually diminishes [54, 
55]. Obviously, this mechanism also applies after RYGB 
and LSG surgery. General pharmacokinetic studies in sub-
jects undergoing RYGB have been reviewed and revealed 
that 68% of all investigated drugs had increased maximum 
plasma concentrations (Cmax) and/or decreased time to 
maximum plasma concentration (Tmax) after a RYGB, com-
pared to controls or before surgery. Additionally, 36% of 
the drugs had increased area under the plasma concentra-
tion-time curve after surgery [51]. Thus, the pharmacoki-
netics of oral administered opioids would be expected to 
change in subjects undergoing bariatric surgery.
6.3   Pharmacokinetics of opioids after 
bariatric surgery
To our knowledge, the pharmacokinetics of orally admin-
istered opioids in subjects undergoing bariatric surgery, 
have only been addressed in two studies; both being in 
subjects undergoing RYGB surgery. Lloret-Linares et  al. 
(2014) studied pharmacokinetics of an oral administered 
morphine solution before and after RYGB. Tmax decreased 
7.5 times, Cmax increased 3.3 times and the area under the 
plasma concentration-time curve was increased 1.6 times 
6  months after surgery compared to before surgery [62]. 
The study lacked a control group, thus changes could 
be related to weight loss rather than other physiological 
changes. In another study the pharmacokinetics of a mor-
phine controlled release formulation was investigated in 
subjects undergoing RYGB surgery and weight-matched 
controls. No significant difference in any of the studied 
pharmacokinetic parameters was demonstrated [63]. 
Thus, the hypothetic pathophysiological changes might 
not have any significant impact on the pharmacokinetics 
of morphine for subjects who underwent RYGB surgery.
The pharmacokinetics of orally administered drugs 
greatly depends on formulation type, physiochemical 
properties of the drug, lean body mass and type of bari-
atric surgery. Thus, in order to achieve optimal effect of 
a drug, dose regulations might be necessary, especially 
during the first years after surgery [64]. However, the 
influence of bariatric surgery on the pharmacokinetic fate 
of drugs is not fully understood and therapeutic failures 
may occur. Other theories suggest that bariatric surgery 
may centrally decrease the opioid signaling effect, imply-
ing an increased risk of addiction [65]. Future studies 
aiming at creating clinical decision support tools based 
on  modeling of the pharmacokinetic-pharmacodynamic 
relationships using physiological-based pharmacokinetic 
models are warranted in order to optimize medication 
therapy, including opioids, for this population.
6.4   Adverse events and addiction
A limited number of studies have evaluated adverse effects 
due to opioid therapy in subjects who underwent bariat-
ric surgery. Increased Cmax and shorter Tmax could increase 
the risk of reaching toxic levels and occurrence of adverse 
events, especially for drugs with a narrow therapeutic 
index. Rapid increase in plasma levels of alcohol, hypnot-
ics and narcotics, has been associated with a higher risk of 
intoxication and addiction [66]. Thus, subjects who under-
went bariatric surgery are theoretically at higher risk for 
adverse events if opioid doses are not adjusted. A higher 
degree of drowsiness have been reported among subjects 
who underwent RYGB surgery compared to controls fol-
lowing a controlled release formulation of morphine [63]. 
Elevating opioid doses could also change pharmacoki-
netic parameters more drastically in subjects who under-
went RYGB surgery depending on the formulation, thus 
enhancing risks of adverse events [62, 63].
The addictive, euphoric rush is influenced by rapid 
absorption rates rather than actual opioid concentrations 
in the central nervous system, hypothetically making sub-
jects undergoing bariatric surgery more prone to addic-
tion. Empirical data have demonstrated a correlation 
between obesity, overeating and substance abuse [67]. 
The exact impact of the physiological changes following 
bariatric surgery remains unclear, but may play a predom-
inant role.
6.5   Risk factors for persistent opioid use
In a few studies the possible risk factors for persistent 
opioid use after bariatric surgery have been investigated 
and the results were conflicting [7, 44, 47]. Extraordi-
nary high food consumption, resulting in obesity, may 
be a coping strategy, related to addictive behavior, and 
decreased opioid signaling, in some subjects, and bari-
atric surgery may not address the subjects’ underlying 
psychosocial problems [48, 65, 68]. Subjects with morbid 
obesity who underwent bariatric surgery may be extra 
vulnerable to opioid misuse and addiction, because the 
prevalence of risk factors such as metal health disor-
ders is higher in this population [47, 69]. In a study by 
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Raebel et  al. (2014) it was found that use of opioids, 
non-opioid analgesics, antianxiety agents, and tobacco 
before bariatric surgery were associated with persistent 
opioid use after bariatric surgery. Additionally, they 
found that persistent opioid use were associated with 
younger age [44], contrary, in another study an associa-
tion with older age was identified [47]. New persistent 
opioid use was also associated with current tobacco 
use and multi-comorbidity. New persistent opioid users 
were less likely to be Caucasian, married, or living with 
a partner [47].
King et  al. (2017) further identified multiple risk 
factors for initiating or continuing opioid use after bari-
atric surgery, including higher pain-level before surgery, 
little/no pain improvement, having public health insur-
ance, subsequent surgery, non-opioid analgesic use, and 
continued benzodiazepine use [7]. In a survey-based study 
it was found that subjects using low opioid doses just after 
bariatric surgery required few opioid refills [41]. In general 
socioeconomic factors and addiction possibly play a role 
for persistent opioid use [47, 70]. However, more detailed 
information on sociodemographic factors, comorbidities, 
medication use, opioid type and formulation in public 
health-care systems are warranted. An overview of risk 
factors for persistent opioid use after bariatric surgery are 
presented in Table 3 [44, 47].
6.6   Clinical outcomes
Postoperative pain management in bariatric surgery is 
partly based on opioids, since sufficient pain manage-
ment (with opioids) decrease the risk of chronic postop-
erative pain [42]. However, regardless of the increasing 
awareness of possible misuse and related comorbidi-
ties in persistent opioid use, the potential impact of 
persistent opioid use after bariatric surgery, on long-term 
outcomes such as adverse events, addiction, and comor-
bidity, is still unknown. In general, persistent opioid 
users have been found to have lower physical quality 
of life, compared to the general population [8, 47, 71]. 
Smith et al. (2018) found that subjects with new persis-
tent opioid use 1 year after bariatric surgery had lower 
weight loss and metabolic benefits from the surgery, 
compared to subjects not being persistent opioid users 
[47]. This could limit remission from obesity related 
disease. However, this has not yet been investigated. 
Subjects with new persistent opioid use after bariatric 
surgery also had worse mental health and reported less 
satisfaction with the surgery [8, 47]. Raebel et al. (2013) 
also aimed to determine the association between opioid 
dose and BMI changes after bariatric surgery, but found 
no association [40].
New persistent opioid use could be a result of com-
plications following bariatric surgery, resulting in e.g. 
chronic abdominal pain. Thus, results might be con-
founded by indication. As earlier stated postoperative 
pain should not be undertreated. However, it is recom-
mended that guidelines and withdrawal-strategies on 
proper prescription of opioids after bariatric surgery are 
followed, in order to limit additional long-term opioid 
prescribing, without clinical indications [47, 72, 73]. Per-
sistent opioid use after bariatric surgery were associated 
with some negative outcomes (Fig. 3) [8, 40, 47]. However, 
more outcomes are to be investigated before appropriate-
ness of persistent opioid use in subjects who underwent 
bariatric surgery can be determined.
Table 3: Risk factors for persistent opioid users after bariatric surgery.
– Pain before surgery
– Lack of/little pain improvement
– Opioids before surgery (especially high opioid doses)
– Non-opioid analgesic use
– Benzodiazepine use
– Subsequent surgery
– Higher/lower age
– Smoking status
– Ethnicity
– Marital status
– Public health insurance
– No withdrawal plan
Fig. 3: Outcomes in persistent opioid users after bariatric surgery. 
Known and expected outcomes from persistent opioid use after 
bariatric surgery, including possible interactions.
248      Simoni et al.: Pain and opioid use after bariatric surgery
6.7   Economic consequences
Besides the goal of decreased obesity related comorbidity 
level, bariatric surgery is expected to decrease the long-
term health care costs in subjects with morbid obesity. 
Results from previous studies have proven that bariatric 
surgery is effective in reducing obesity related comor-
bidities, which could reduce the health care costs [10, 74]. 
However, since persistent opioid use following bariatric 
surgery gave raise to poorer physiological and psychologi-
cal outcomes [47, 71], possible increased amount of health 
care system contacts and possible lack of remission or new 
onset of obesity related comorbidity, suggest that reduc-
tions in costs are not obtained in the new persistent opioid 
users after bariatric surgery [25, 75, 76]. Opioid use before 
bariatric surgery, or other elective abdominal surgeries, 
were recently found to be associated with greater overall 
health care costs both at 90, 180, and 365 days following 
surgery [49]. However, results on long-term economic out-
comes of persistent opioid use after bariatric surgery have 
not yet been investigated and studies must be carried out 
to advance knowledge within this field.
6.8   Study strengths and limitations
The aim of this review was to assess the existing data on 
prevalence, possible mechanisms, risk factors, and out-
comes regarding occurrence of chronic abdominal pain 
and persistent opioid use after bariatric surgery. To cover 
these important clinical problems and the undefined rela-
tions multiple structured searches in the most relevant 
biomedical database (PubMed) were found to be the most 
appropriate method. The one-database design is a limi-
tation of the present study, in regard of literature cover-
age. However, the scientific areas were attempted further 
covered through cross-referencing the included articles.
Unfortunately, the majority of the identified literature 
in the present study cover populations who had under-
gone RYGB surgery, indicating, that the existing evidence 
regarding persistent opioid use and especially abdominal 
pain after bariatric surgery is lacking in subjects under-
going LSG surgery [22–26, 28, 29]. Two studies identified 
an overall prevalence on abdominal pain after bariat-
ric surgery including small proportions (7%) of subjects 
who underwent LSG [8, 30], and only one identified study 
investigated the prevalence separate in subjects undergo-
ing LSG and found a prevalence of acute abdominal pain 
between 3 and 11% [27]. This is a limitation in regard of 
generalization of the chronic abdominal pain status after 
bariatric surgeries, since clinical outcomes may differ 
significantly between subjects who have undergone dif-
ferent bariatric procedures. E.g. studies suggest that 
substance abuse may be more common after RYGB than 
other bariatric procedures [18, 48, 77]. The absence of suf-
ficient evidence, apply reasons to believe that these com-
plications may not affect subjects in the same extent after 
undergoing LSG surgery. However, future studies should 
investigate this issue to clarify the presence of these 
important clinical problems in the largest population of 
subjects undergoing bariatric surgery worldwide [18].
7   Conclusion and perspectives
Abdominal pain remains the major cause for health care 
contacts after bariatric surgery and especially RYGB 
surgery. Explanations include behavioral, dietary, ana-
tomical, or functional disorders, which may be related 
to surgery. In general, persistent opioid use is prevalent 
before bariatric surgery, but the prevalence increases after 
surgery and higher doses are often used. This could be 
triggered by chronic pain symptoms, although socioeco-
nomic factors also affect whether subjects discontinue the 
opioid use. Theories on altered opioid absorption after 
bariatric surgery are still to be addressed and are of most 
importance as opioids are widely used in this population. 
Unfortunately, important factors as weight loss, metabolic 
benefits, and thus, remission from obesity related comor-
bidities and achievement of the health economic benefits 
following bariatric surgery may be limited in subjects with 
persistent opioid use after bariatric surgery.
Future studies aiming at creating clinical decision 
support tools based on recognition of social, physiological, 
and psychological circumstances and modeling of the 
pharmacokinetic-pharmacodynamic-relationships seems 
to be warranted, in order to identify subjects at risk for per-
sistent opioid use and optimize the treatment for this pop-
ulation, to minimize side-effects and optimize pain relief.
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